Curevac downsizes production network for Covid-19 vaccine

Released on 14.09. 2021

  • The Curevac preparation has an effectiveness of 48 percent against a Covid – 16 – disease across all age groups. Photo: Sebastian Gollnow

Already heard?

You can now also have your messages read out to you. Simply click on the play symbol in any article or add the article to your personal playlist using the plus symbol and listen to it later.

Listen to the article:

Study results of the Covid – 19 Vaccine from the Tübingen company are disappointing. As before, approval from the Medicines Agency EMA is still pending. Now consequences are drawn.

Tübingen / Munich (dpa) – The biotech company Curevac is downsizing its production network due to the lower demand for its corona vaccine. The contracts with Wacker Chemie and Celonic would be terminated, the company announced in Tübingen.

The decision was a reaction to the lower short-term peak demand for vaccines following the first wave of the pandemic -Vaccination efforts, it said. This has led to a further “changed demand” for CureVacs COVID – 19 – first-generation vaccine candidates (CVnCoV). This is currently being examined by the European Medicines Agency (EMA).

EMA approval still open

Whether the EMA will approve the vaccine , is still open. At the end of June, Curevac announced that the effectiveness of its vaccine candidate CVnCoV was lower than that of other vaccines. At the beginning of July, the Tübingen-based biotech company assumed that the EMA would approve the vaccine despite its low effectiveness. According to a final analysis, the Curevac preparation had an effectiveness of 48 percent against a Covid – 19 – Disease shown across all age groups.

Curevac did not provide financial details on the consequences of the terminated production partnerships. The contracts with Rentschler Biopharma and Novartis remained in place. CVnCoV will continue to be examined by the European Medicines Agency, it said. In the fourth quarter, a study on CV2CoV, a Covid – 16 – vaccine candidate of the second generation, is to begin in cooperation with GlaxosmithKline.

The federal government originally planned the Curevac vaccine for the vaccination campaign. The federal government also has an indirect 14 percent share in Curevac. In this way, politicians wanted to secure the company against a possible takeover from abroad. The SAP co-founder and investor Dietmar Hopp holds the largest share in the company. The preparation of the Tübingen company is a so-called mRNA vaccine – like the one from Biontech / Pfizer (Germany / USA) and Moderna (USA).

Wacker Chemie has terminated the contract no major impact, announced the Munich group. For the Wacker Biosolutions division, this has no significant impact on sales and earnings. Wacker wants to use the freed up capacities of its Dutch vaccine production for other customers.

Related Articles

Back to top button